No Detail Found!

Determination of Xanthine Oxidase and Calprotectin and Some Biochemical Parameters in Diabetic Nephropathy Serum of Iraqi Patients

Author(s)
Zina J. Ghaib Department of Applied Pathological Analysis, College of Science, Al-Nahrain University, Baghdad, Iraq
Rasha M. Kamil Department of Basic Science, College of Dentistry, Mustansiriyah University, Baghdad, Iraq
Amal Jabbar Ghaib AL-Mustafa University, Baghdad, Iraq
Abstract
Objective: Diabetic Nephropathy (DN) is a major long-term severe microvascular complication of diabetes mellitus and the current leading cause of end-stage kidney disease. It accounts for up to 40% of patients requiring renal replacement therapy. The risk of end-stage kidney failure has been associated with an increase in the level of a new biomarker, xanthine oxidase and calprotectin, used to assess the severity of kidney injury. Methods: Blood samples were collected from 30 individuals diagnosed with DN disease and 30 individuals with diabetes but without kidney disease, who visited the National Diabetes Centre at the University of Al-Mustansiriyah, along with 28 control subjects. An enzyme-linked immunosorbent assay was used to assess serum xanthine oxidase (XOD) and Calprotectin (Calp) and a UV-Visible spectrophotometer was used to evaluate other biochemical parameters. Results: The mean serum XOD activity (2.04±0.38 ng/ml) in DN was significantly greater than the corresponding values for the controls (0.95±0.12 ng/ml) and the mean serum Calp (173.46±29.56 ng/ml) in DN Patients was significantly greater than the corresponding values for the controls (43.26±5.88 ng/ml). The optimal cut-off value for CALP sensitivity of 86.3% and specificity of 82.1% and the AUC for control and DN is 0.844 and for control versus diabetic, it is 0.853, while XOD activity showed a high sensitivity of 76.5% and specificity of 89.9% to distinguish between control and DN, so the results show the AUC = 0.833 for control vs. DN and AUC for control and diabetes is 0.863. These high sensitivity and specificity values highlight the reliability of CALP and XOD as significantly associated with diabetic nephropathy.
Publication Details
Page(s) 168-173
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 6, Year: 2026

Request the full text from PASTIC

Keywords
Xanthine oxidase, Diabetic Nephropathy, Calprotectin, ROC
References
Keane W.F. . .Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: The RENAAL study. Clinical Journal of the American Society of Nephrology, 1(2006) : 1-7.
.2024 .Xanthine oxidoreductase inhibition ameliorates high glucose-induced glomerular endothelial injury by activating AMPK through the purine salvage pathway. ” Scientific Reports, 14 : 11167.
Klisic .2018 .Xanthine oxidase and uric acid as independent predictors of albuminuria in patients with diabetes mellitus type 2.” Clinical and Experimental Medicine. , 18 : 283-290.
Hasan M. .2022 .Assessment of the relationship between serum xanthine oxidase levels and type 2 diabetes: A crosssectional study. ” Scientific Reports, 12 : 20816.
Nakatani S. .2021 .Plasma xanthine oxidoreductase activity associated with glycaemic control in patients with pre-dialysis chronic kidney disease. ” Kidney and Blood Pressure Research, 46 : 475-483.
Washio K. .2020 .Xanthine oxidoreductase activity correlates with vascular endothelial dysfunction in patients with type 1 diabetes. ” Acta Diabetologica, 57 : 31-39.
Shabani F. .2020 .Human & Experimental Toxicology. , 39 : 1031-1045.
Garcia V. .2022 .A structural perspective on calprotectin as a ligand of receptors mediating inflammation and potential drug target. ” Biomolecules, 12 : 519.
Sekimoto R. .2012 .High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice. ” Biochemical and Biophysical Research Communications, 419 : 782-789.
Oosterwijk M.M. .2020 .Determinants of increased serum calprotectin in patients with type 2 diabetes mellitus. International Journal of Molecular Sciences, 21 : 8075.
Ortega F.J. .2012 .Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. European Journal of Endocrinology, 167 : 569-578.
Jukic A. .2021 .Calprotectin: From biomarker to biological function. ” Gut, 70 : 1978-1988.
Afify M. .2022 .The relationship between serum calprotectin and peripheral neuropathy in a sample of Egyptian type 2 diabetic patients. ” Ain Shams Medical Journal, 73 : 153-169.
Mostafa ,April 2024 . .Serum calprotectin in patients with type 2 diabetes mellitus and its relation to microvascular complications.” Alexamed ePosters. , 6(2) : 13-14.
Tan C.E. .2001 .Cardiovascular risk factors and LDL sub fraction profile in type 2 diabetes mellitus subjects with good glycaemic control. ” Diabetes Research and Clinical Practice, 51 : 107-114.
Annette M.,Jeffrey B. .2003 .Aging and insulin secretion. American Journal of Physiology-Endocrinology and Metabolism, : .
Majid .2018 .Study of some biochemical parameters for patients with type II diabetes mellitus in Thi-Qar Governorate. ” Journal of Pharmaceutical Sciences and Research, 10(11) : 2938-2941.
Ullah .2023 .Assessment of serum urea and creatinine levels in diabetic patient. BioScientific Review, 5(3) : .
Liu X. . .Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention. ” Renal Failure, 44(2022) : 790-805.
Rasool Ali,Abdul Ali .2023 .Mawj Abdel Razzak Ahmed. “Impact of activity of xanthine oxidase on some biomarkers in patients with kidney stones in Iraqi patients. ” Mustansiriya Medical Journal, 27 : 23.
Korsmo . .Emerging roles of xanthine oxidoreductase in chronic kidney disease. ” Antioxidants, 13(2024) : 712.
Maejima I. .2013 .Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. The EMBO Journal, 32 : 2336-2347.
Lusco M. .2017 .AJKD Atlas of renal pathology: Gouty nephropathy. American Journal of Kidney Diseases, 69 : e5-e6.
Cao L. .2021 .Performance of ultrasound in the clinical evaluation of gout and hyperuricemia. ” Journal of Immunology Research, : 5550626.
Hasan ,December .2022 .Assessment of the relationship between serum xanthine oxidase levels and type 2 diabetes: A cross-sectional study. ” Scientific Reports, 12(1) : .
Oosterwijk M.M. .2020 .Determinants of increased serum calprotectin in patients with type 2 diabetes mellitus. International Journal of Molecular Sciences, 21 : 8075.
Mandrekar J.N. . .Simple statistical measures for diagnostic accuracy assessment. ” Journal of Thoracic Oncology, 5(2010) : 763-764.
Akpotaire P.A. and S.A.,Seriki P.A. and S.A. . .Assessment and correlation of serum urea and creatinine levels in normal, hypertensive and diabetic persons in Auchi, Nigeria. Clinical Research, 7(2023) : 7-16.
0

Citations

0

Downloads

15

Views